These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30947657)

  • 1. The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer.
    Qu J; Kamal MA; Yuan C
    Curr Pharm Des; 2019; 25(8):856-861. PubMed ID: 30947657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
    Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
    J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
    Bhardwaj V; Tan YQ; Wu MM; Ma L; Zhu T; Lobie PE; Pandey V
    Cancer Lett; 2021 Apr; 502():97-107. PubMed ID: 33429007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of pathological grade and prognosis-associated lncRNA for ovarian cancer.
    Chen Y; Bi F; An Y; Yang Q
    J Cell Biochem; 2019 Sep; 120(9):14444-14454. PubMed ID: 31034644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Long Non-Coding RNAs in Ovarian Cancer.
    Nikpayam E; Tasharrofi B; Sarrafzadeh S; Ghafouri-Fard S
    Iran Biomed J; 2017 Jan; 21(1):3-15. PubMed ID: 27664137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
    Song J; Zhang W; Wang S; Liu K; Song F; Ran L
    Int J Oncol; 2018 Aug; 53(2):866-876. PubMed ID: 29749482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pivotal role of long non-coding RNAs as potential biomarkers and modulators of chemoresistance in ovarian cancer (OC).
    Malgundkar SH; Tamimi Y
    Hum Genet; 2024 Feb; 143(2):107-124. PubMed ID: 38276976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression.
    Guo Q; Cheng Y; Liang T; He Y; Ren C; Sun L; Zhang G
    Sci Rep; 2015 Dec; 5():17683. PubMed ID: 26631459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of long non-coding RNA AFAP1-AS1 in human malignant tumors.
    Ji D; Zhong X; Jiang X; Leng K; Xu Y; Li Z; Huang L; Li J; Cui Y
    Pathol Res Pract; 2018 Oct; 214(10):1524-1531. PubMed ID: 30173945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA HOTTIP is a significant indicator of ovarian cancer prognosis and enhances cell proliferation and invasion.
    Zou T; Wang PL; Gao Y; Liang WT
    Cancer Biomark; 2019; 25(2):133-139. PubMed ID: 30452402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression.
    Liu Y; Zong ZH; Guan X; Wang LL; Zhao Y
    Gene; 2017 Oct; 633():42-47. PubMed ID: 28864116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer.
    Worku T; Bhattarai D; Ayers D; Wang K; Wang C; Rehman ZU; Talpur HS; Yang L
    Cell Physiol Biochem; 2017; 44(3):948-966. PubMed ID: 29179183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNAs in ovarian cancer.
    Wang JY; Lu AQ; Chen LJ
    Clin Chim Acta; 2019 Mar; 490():17-27. PubMed ID: 30553863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients.
    Xu QF; Tang YX; Wang X
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4440-4447. PubMed ID: 30058681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of lncRNA TUBA4B is Associated with Poor Prognosis for Epithelial Ovarian Cancer.
    Zhu FF; Zheng FY; Wang HO; Zheng JJ; Zhang Q
    Pathol Oncol Res; 2018 Apr; 24(2):419-425. PubMed ID: 28578489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers.
    Panoutsopoulou K; Avgeris M; Scorilas A
    Expert Rev Mol Diagn; 2018 Nov; 18(11):963-979. PubMed ID: 30338716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes.
    Tripathi MK; Doxtater K; Keramatnia F; Zacheaus C; Yallapu MM; Jaggi M; Chauhan SC
    Drug Discov Today; 2018 Sep; 23(9):1635-1643. PubMed ID: 29698834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.